Oncolytics Debt To Equity from 2010 to 2024

ONCY Stock  USD 0.93  0.02  2.11%   
Oncolytics Biotech Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2024. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.005601
Current Value
0.009046
Quarterly Volatility
0.00437725
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 77 K, Interest Expense of 637.6 K or Selling General Administrative of 16.9 M, as well as many indicators such as Price To Sales Ratio of 66.83, Dividend Yield of 0.0 or PTB Ratio of 4.5. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.
  
Check out the analysis of Oncolytics Biotech Correlation against competitors.
For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Latest Oncolytics Biotech's Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Oncolytics Biotech over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Oncolytics Biotech's Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncolytics Biotech's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.02 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Oncolytics Debt To Equity Regression Statistics

Arithmetic Mean0.01
Geometric Mean0.01
Coefficient Of Variation69.30
Mean Deviation0
Median0
Standard Deviation0
Sample Variance0.000019
Range0.0168
R-Value(0.31)
Mean Square Error0.000019
R-Squared0.09
Significance0.27
Slope(0.0003)
Total Sum of Squares0.0003

Oncolytics Debt To Equity History

2024 0.009046
2023 0.005601
2011 0.00487
2010 0.0217

About Oncolytics Biotech Financial Statements

Oncolytics Biotech investors use historical fundamental indicators, such as Oncolytics Biotech's Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncolytics Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 0.01  0.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.